Virogin Biotech and MD Anderson Announce Strategic Collaboration to Accelerate Oncolytic Virus Research and Development for Treating Advanced Cancers

Virogin Biotech and The University of Texas MD Anderson Cancer Center announced a strategic collaboration to accelerate the development of investigational treatments, including oncolytic viruses and immunotherapies, for patients with advanced cancers.
[Virogin Biotech (Globe Newswire, Inc.)]
Press Release

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News